Ensysce Biosciences Statistics
Want to see ENSC full AI Analyst Report?
Ensysce Biosciences (ENSC) Stock Statistics & Valuation Metrics
Total Valuation
Ensysce Biosciences has a market cap or net worth of $6.40M. The enterprise value is $2.97M.
- Market Cap
- $6.40M
- Enterprise Value
- $2.97M
Share Statistics
Ensysce Biosciences has 19,456,795 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 19,456,795
- Owned by Insiders
- 4.71%
- Owned by Institutions
- 0.46%
Financial Efficiency
Ensysce Biosciences’s return on equity (ROE) is -3.17 and return on invested capital (ROIC) is -320.89%.
- Return on Equity (ROE)
- -3.17
- Return on Assets (ROA)
- -1.37
- Return on Invested Capital (ROIC)
- -320.89%
- Return on Capital Employed (ROCE)
- -3.55
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.13M
- Employee Count
- 9
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Ensysce Biosciences is -0.13. Ensysce Biosciences’s PEG ratio is 0.01.
- PE Ratio
- -0.13
- PS Ratio
- 6.04
- PB Ratio
- -6.03
- Price to FCF
- -0.78
- Price to Operating Cash Flow
- -0.53
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, Ensysce Biosciences had revenue of 0 and earned -10.18M in profits. Earnings per share was -3.98.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -10.24M
- Pretax Income
- -10.18M
- Net Income
- -10.18M
- EBITDA
- -10.15M
- Earnings Per Share (EPS)
- -3.98
Cash Flow
In the last 12 months, operating cash flow was -8.86M and capital expenditures -123,643, giving a free cash flow of -8.98M billion.
- Operating Cash Flow
- -8.86M
- Free Cash Flow
- -8.98M
- Free Cash Flow per Share
- -0.69
Dividends & Yields
Ensysce Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -130.05%
- Earnings Yield
- -272.91%
Stock Price Statistics
- Beta
- 3.17
- 52-Week Price Change
- -84.15%
- 50-Day Moving Average
- 0.45
- 200-Day Moving Average
- 0.41
- Relative Strength Index (RSI)
- 28.12
- Average Volume (3m)
- 1.03M
Important Dates
Ensysce Biosciences upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 19, 2026
- Next Earnings Date
- Nov 16, 2026
- Ex-Dividend Date
- ―
Financial Position
Ensysce Biosciences as a current ratio of 1.59, with Debt / Equity ratio of 9.54%
- Current Ratio
- 1.59
- Quick Ratio
- 1.59
- Debt to Market Cap
- 0.13
- Net Debt to EBITDA
- 0.39
- Interest Coverage Ratio
- -545.69
Taxes
In the past 12 months, Ensysce Biosciences has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Ensysce Biosciences EV to EBITDA ratio is -0.51, with an EV/FCF ratio of -0.72.
- EV to Sales
- 5.52
- EV to EBITDA
- -0.51
- EV to Free Cash Flow
- -0.72
- EV to Operating Cash Flow
- -0.73
Balance Sheet
Ensysce Biosciences has $676.70K in cash and marketable securities with $196.84K in debt, giving a net cash position of $479.86K billion.
- Cash & Marketable Securities
- $676.70K
- Total Debt
- $196.84K
- Net Cash
- $479.86K
- Net Cash Per Share
- $0.02
- Tangible Book Value Per Share
- -$0.09
Margins
Gross margin is 100.00%, with operating margin of -1087.47%, and net profit margin of -1084.23%.
- Gross Margin
- 100.00%
- Operating Margin
- -1087.47%
- Pretax Margin
- -1084.28%
- Net Profit Margin
- -1084.23%
- EBITDA Margin
- -1082.78%
- EBIT Margin
- -1083.90%
Analyst Forecast
The average price target for Ensysce Biosciences is $2.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $2.00
- Price Target Upside
- 509.76% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- -39.29%
- EPS Growth Forecast
- 27.41%
Scores
- Smart Score
- ―
- AI Score
- 44
